Dr Michael Ross Wexler, MD | |
12450 Wayzata Blvd, Suite 215, Minnetonka, MN 55305-1978 | |
(952) 546-6566 | |
(952) 512-0038 |
Full Name | Dr Michael Ross Wexler |
---|---|
Gender | Male |
Speciality | Allergy/immunology |
Experience | 42 Years |
Location | 12450 Wayzata Blvd, Minnetonka, Minnesota |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093732984 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207K00000X | Allergy & Immunology | 28446 (Minnesota) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Advancements In Allergy And Asthma Care Ltd | 9830176502 | 6 |
News Archive
More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer.
A reduced dose of alteplase has failed to prove itself noninferior to the standard dose in a predominantly Asian population of patients with ischaemic stroke.
Researchers at the Texas Children's Hospital Center for Vaccine Development, USA, have published a report on the preprint server bioRxiv that describes a yeast-expressed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) protein, a key target of current vaccine development efforts.
A disaster or tragedy is unexpected and often brings out strong emotions. The Disaster Distress Helpline 1-800-985-5990 can provide immediate counseling to anyone who needs help in dealing with the tragedy in Boston.
Myotec Therapeutics, Ltd. and Hybrid BioSystems, Ltd. today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets.
› Verified 6 days ago
Entity Name | Advancements In Allergy And Asthma Care Ltd |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1619994696 PECOS PAC ID: 9830176502 Enrollment ID: O20040630000943 |
News Archive
More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer.
A reduced dose of alteplase has failed to prove itself noninferior to the standard dose in a predominantly Asian population of patients with ischaemic stroke.
Researchers at the Texas Children's Hospital Center for Vaccine Development, USA, have published a report on the preprint server bioRxiv that describes a yeast-expressed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) protein, a key target of current vaccine development efforts.
A disaster or tragedy is unexpected and often brings out strong emotions. The Disaster Distress Helpline 1-800-985-5990 can provide immediate counseling to anyone who needs help in dealing with the tragedy in Boston.
Myotec Therapeutics, Ltd. and Hybrid BioSystems, Ltd. today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Michael Ross Wexler, MD 12450 Wayzata Blvd, Suite 215, Minnetonka, MN 55305-1978 Ph: (952) 546-6566 | Dr Michael Ross Wexler, MD 12450 Wayzata Blvd, Suite 215, Minnetonka, MN 55305-1978 Ph: (952) 546-6566 |
News Archive
More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer.
A reduced dose of alteplase has failed to prove itself noninferior to the standard dose in a predominantly Asian population of patients with ischaemic stroke.
Researchers at the Texas Children's Hospital Center for Vaccine Development, USA, have published a report on the preprint server bioRxiv that describes a yeast-expressed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) protein, a key target of current vaccine development efforts.
A disaster or tragedy is unexpected and often brings out strong emotions. The Disaster Distress Helpline 1-800-985-5990 can provide immediate counseling to anyone who needs help in dealing with the tragedy in Boston.
Myotec Therapeutics, Ltd. and Hybrid BioSystems, Ltd. today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets.
› Verified 6 days ago